Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study

BACKGROUND: The standard of care for myelodysplastic syndromes is hypomethylating agents such as azacitidine. However, responses to azacitidine are generally temporary, and outcomes after hypomethylating agent failure are dismal. Therefore, the development of more effective treatments is crucial to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Haematol
Main Authors: DiNardo, Courtney D, Daver, Naval, Jabbour, Elias, Kadia, Tapan, Borthakur, Gautam, Konopleva, Marina, Pemmaraju, Naveen, Yang, Hui, Pierce, Sherry, Wierda, William, Bueso-Ramos, Carlos, Patel, Keyur P, Cortes, Jorge E, Ravandi, Farhad, Kantarjian, Hagop M, Garcia-Manero, Guillermo
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4936479/
https://ncbi.nlm.nih.gov/pubmed/26687423
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(14)00026-X
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados